CRA was retained by a pharmaceutical company to assist in settlement negotiations with a potential generic competitor. As part of this project, CRA prepared a flexible valuation model to estimate the expected profits from the perspective of the generic competitor under various assumptions. CRA also prepared a decision probability tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.
Overview of IP litigation in the US involving Chinese companies
This underscores China’s growing commitment to address intellectual property (IP) disputes with foreign entities. While litigators and companies are evaluating...